Home  »  Market Insights   »  Xiaobai Mumbai Inc. (HX) Stock Surges as Presence ...

Xiaobai Mumbai Inc. (HX) Stock Surges as Presence on Radiation Oncology Market Expands

Xiaobai Mumbai Inc. (HX) stock prices were up by 31.11% as of the market closing on October 16th, 2021. This brought the price per share up to USD$5.90. Subsequent pre-market fluctuations have seen the stock surge by 24.92%, bringing it up to USD$7.37.

Do You Own These 7 Inflation-Survival Stocks?

Inflation is still near 40-year highs and rising prices are putting a big dent in our wallets. Unless you find out how to protect your portfolio and outpace inflation, you'll keep being at the mercy of economic factors out of your control. Especially since the price of electricity, food, and shelter are creeping up higher than ever. In this special report, I detail 7 stocks to help you survive and thrive in today's market. They're backed by solid companies, positioned to profit during tough economic times, and offer out-sized dividends to help you outpace inflation.

Click here to get your free copy of the report

Sponsored

Entry into Oncology Market

September 28th, 2021 saw HX stock announce its intention to enter the radiation oncology services market in the United States. The social e-commerce platform that is based in China recently established We Health Ltd. We Health is a subsidiary based in New York with the aim of accessing the expansive cancer therapy and radiation oncology business in the United States. The company’s Board of Directors has facilitated this development with the appointment of Ms. Yilin Wang as Co-Chief Executive Officer. Ms. Wang brings her extensive experience to the table, with which the company hopes to reach new heights. This experience ranged from medical health and health management to medical technology-related businesses.

Scope of Cancer Market

Cancer continues to be a front-running cause of deaths around the world, with the World Health Organization Global Cancer Observatory reporting nearly 18 million cancer cases all over the globe in the 2018 year alone. The number of new cancer cases that are diagnosed every year is expected to increase to roughly 25 million by 2030 year. Radiotherapy is one of the most common treatments for cancer, having been adopted widely and indicated steady growth over the years. As per the World Health Organization, more than 50% of cancer patients require radiotherapy as an integral part of their cancer care. Radiotherapy is often used to treat the most common types of cancers, signaling its massive scope.

HX Stock Builds on Success

HX stock has conducted the appropriate market research and has come to the conclusion that there are extensive opportunities for radiation oncology centers along the East Coast of the U.S to address the needs of patients. The catering for patients spans several ethnicities as a result of the company’s healthcare experience and language expertise.

Future Outlook for HX Stock

HX is poised to capitalize on the massive scope of opportunities afforded to it as a result of its foray into the oncology market space. The company is keen to establish and expand its market footprint in a bid to usher in unprecedented growth. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate significant and sustained increases in shareholder value over the long term.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

385

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam